S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
Log in
NASDAQ:CLRB

Cellectar Biosciences Stock Forecast, Price & News

$1.92
-0.02 (-0.77 %)
(As of 01/21/2021 10:08 AM ET)
Add
Compare
Today's Range
$1.91
Now: $1.93▼
$1.98
50-Day Range
$1.52
MA: $2.10▼
$2.77
52-Week Range
$1.01
Now: $1.93▼
$3.33
Volume11,730 shs
Average Volume1.79 million shs
Market Capitalization$87.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is targeted to treat solid tumors. It has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; Avicenna Oncology GMBH to develop CLR 2000 Series; Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series; and Orano Med to develop novel PDCs. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences logo

MarketRank™

Overall MarketRank™

1.70 out of 5 stars

Medical Sector

220th out of 1,928 stocks

Pharmaceutical Preparations Industry

104th out of 774 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLRB
Previous Symbol
CUSIPN/A
CIK1279704
Webwww.cellectar.com
Phone608-441-8120
Employees8

Debt

Debt-to-Equity Ratio0.01
Current Ratio5.01
Quick Ratio5.01

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.84 per share
Price / Book2.29

Profitability

EPS (Most Recent Fiscal Year)($1.84)
Net Income$-14,090,000.00
Net MarginsN/A
Return on Equity-129.44%
Return on Assets-90.76%

Miscellaneous

Outstanding Shares45,409,000
Market Cap$87.41 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable
$1.92
-0.02 (-0.77 %)
(As of 01/21/2021 10:08 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

How has Cellectar Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Cellectar Biosciences' stock was trading at $1.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLRB stock has increased by 9.4% and is now trading at $1.97.
View which stocks have been most impacted by COVID-19.

Is Cellectar Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cellectar Biosciences stock.
View analyst ratings for Cellectar Biosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cellectar Biosciences?

Wall Street analysts have given Cellectar Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cellectar Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Cellectar Biosciences' CEO?

1,428 employees have rated Cellectar Biosciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Cellectar Biosciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Cellectar Biosciences.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.05.
View Cellectar Biosciences' earnings history.

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Cellectar Biosciences's stock reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CLRB?

4 brokerages have issued twelve-month price objectives for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they expect Cellectar Biosciences' stock price to reach $5.25 in the next year. This suggests a possible upside of 166.5% from the stock's current price.
View analysts' price targets for Cellectar Biosciences or view Wall Street analyst' top-rated stocks.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 2,640,000 shares, an increase of 161.4% from the December 15th total of 1,010,000 shares. Based on an average trading volume of 1,530,000 shares, the days-to-cover ratio is presently 1.7 days.
View Cellectar Biosciences' Short Interest.

Who are some of Cellectar Biosciences' key competitors?

Some companies that are related to Cellectar Biosciences include Axovant Sciences (AXON), Arbutus Biopharma (ABUS), MEI Pharma (MEIP), Trevena (TRVN), Concert Pharmaceuticals (CNCE), Fortress Biotech (FBIO), Mustang Bio (MBIO), Matinas BioPharma (MTNB), Alpine Immune Sciences (ALPN), VistaGen Therapeutics (VTGN), Cassava Sciences (SAVA), BELLUS Health (BLU), Galecto (GLTO), Kamada (KMDA) and VYNE Therapeutics (VYNE).
View all of CLRB's competitors.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International Co. (S.TO) (S), Bombardier (BDRBF), (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals Inc. (HBM.TO) (HBM).

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the following people:
  • Mr. James V. Caruso, Pres, CEO & Director (Age 62, Pay $664.49k)
  • Mr. Dov Elefant, VP & CFO (Age 54, Pay $155.29k)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 48, Pay $428.23k)
  • Dr. John E. Friend II, M.D., Chief Medical Officer (Age 51)
  • Gregory J. Lynch Esq., Sec.

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.49%). Company insiders that own Cellectar Biosciences stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends for Cellectar Biosciences.

Which institutional investors are buying Cellectar Biosciences stock?

CLRB stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include Dov Elefant, James V Caruso, Jarrod Longcor, and Stephen A Hill.
View insider buying and selling activity for Cellectar Biosciences or or view top insider-buying stocks.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $1.97.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $89.46 million. The biopharmaceutical company earns $-14,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Cellectar Biosciences employs 8 workers across the globe.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is www.cellectar.com.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.